CN102458580A - 作为mek抑制剂的杂环化合物 - Google Patents
作为mek抑制剂的杂环化合物 Download PDFInfo
- Publication number
- CN102458580A CN102458580A CN2009801598607A CN200980159860A CN102458580A CN 102458580 A CN102458580 A CN 102458580A CN 2009801598607 A CN2009801598607 A CN 2009801598607A CN 200980159860 A CN200980159860 A CN 200980159860A CN 102458580 A CN102458580 A CN 102458580A
- Authority
- CN
- China
- Prior art keywords
- fluoro
- indolizine
- tetrahydrochysene
- oxo
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SDWBBDXXTROLQT-UHFFFAOYSA-N C=CC(C(C(Nc(ccc(Br)c1)c1F)=C1F)=C(CCC2)N2C1=O)O Chemical compound C=CC(C(C(Nc(ccc(Br)c1)c1F)=C1F)=C(CCC2)N2C1=O)O SDWBBDXXTROLQT-UHFFFAOYSA-N 0.000 description 1
- HPMZAJKGMQCMNX-UHFFFAOYSA-N CBc(cc1F)ccc1NC(C(C(N)=O)=C1N2CCC1)=C(C)C2=O Chemical compound CBc(cc1F)ccc1NC(C(C(N)=O)=C1N2CCC1)=C(C)C2=O HPMZAJKGMQCMNX-UHFFFAOYSA-N 0.000 description 1
- OWYPSCOKUPQOEG-UHFFFAOYSA-N CC(C(N(CCC1)C1=C1C(NOCC2CC2)=O)=O)=C1Nc(ccc(I)c1)c1F Chemical compound CC(C(N(CCC1)C1=C1C(NOCC2CC2)=O)=O)=C1Nc(ccc(I)c1)c1F OWYPSCOKUPQOEG-UHFFFAOYSA-N 0.000 description 1
- VALUJYZPVDNRIG-UHFFFAOYSA-N CC(C(N(CCC1)C1=C1N(C2=O)S(C3(CC=C)CC3)(=O)=O)=O)=C1N2c(ccc(Br)c1)c1F Chemical compound CC(C(N(CCC1)C1=C1N(C2=O)S(C3(CC=C)CC3)(=O)=O)=O)=C1N2c(ccc(Br)c1)c1F VALUJYZPVDNRIG-UHFFFAOYSA-N 0.000 description 1
- AXOVWPFTRQIJBW-UHFFFAOYSA-N CC(C(N(CCC1)C1=C1NS(C2(CC=C)CC2)(=O)=O)=O)=C1Nc(ccc(Br)c1)c1F Chemical compound CC(C(N(CCC1)C1=C1NS(C2(CC=C)CC2)(=O)=O)=O)=C1Nc(ccc(Br)c1)c1F AXOVWPFTRQIJBW-UHFFFAOYSA-N 0.000 description 1
- VNBKWZJNPLRELJ-UHFFFAOYSA-N CC(C)(C)OC(N(C(C(N1c(c(F)c2)ccc2Br)=C2)=C(CCC3)N3C2=O)C1=O)=O Chemical compound CC(C)(C)OC(N(C(C(N1c(c(F)c2)ccc2Br)=C2)=C(CCC3)N3C2=O)C1=O)=O VNBKWZJNPLRELJ-UHFFFAOYSA-N 0.000 description 1
- SJZNNKAAMAEBQN-DYESRHJHSA-N CC(C)(O[C@@H]1CN23)O[C@H]1C2=C(C(NOCC1CCC1)=O)C(Nc(ccc(Br)c1)c1F)=CC3=O Chemical compound CC(C)(O[C@@H]1CN23)O[C@H]1C2=C(C(NOCC1CCC1)=O)C(Nc(ccc(Br)c1)c1F)=CC3=O SJZNNKAAMAEBQN-DYESRHJHSA-N 0.000 description 1
- WDFDIGNNNDWYOJ-UHFFFAOYSA-N CC(C)N(C(C(N1c(c(F)c2)ccc2Br)=C2F)=C(CCC3)N3C2=O)C1=O Chemical compound CC(C)N(C(C(N1c(c(F)c2)ccc2Br)=C2F)=C(CCC3)N3C2=O)C1=O WDFDIGNNNDWYOJ-UHFFFAOYSA-N 0.000 description 1
- OZHMGVCYJWVQMN-UHFFFAOYSA-N CC1(C)OC(CONC(C(C(Nc(c(F)c2)ccc2I)=C2Cl)=C(CCC3)N3C2=O)=O)CO1 Chemical compound CC1(C)OC(CONC(C(C(Nc(c(F)c2)ccc2I)=C2Cl)=C(CCC3)N3C2=O)=O)CO1 OZHMGVCYJWVQMN-UHFFFAOYSA-N 0.000 description 1
- YJVXFYRZIRNKIO-UHFFFAOYSA-N CCC(N(CC)C1=O)=C(C(NOCCO)=O)C(Nc(c(F)c2)ccc2Br)=C1F Chemical compound CCC(N(CC)C1=O)=C(C(NOCCO)=O)C(Nc(c(F)c2)ccc2Br)=C1F YJVXFYRZIRNKIO-UHFFFAOYSA-N 0.000 description 1
- UQEUVEYMDOOTSE-UHFFFAOYSA-N CCONC(C(C(Nc(c(F)c1)ccc1Br)=C1)=C(CCC2)N2C1=N)=O Chemical compound CCONC(C(C(Nc(c(F)c1)ccc1Br)=C1)=C(CCC2)N2C1=N)=O UQEUVEYMDOOTSE-UHFFFAOYSA-N 0.000 description 1
- 0 N*(CCC1)C1C(OCc1ccccc1)=O Chemical compound N*(CCC1)C1C(OCc1ccccc1)=O 0.000 description 1
- TXQNSSDPDFIHHW-UHFFFAOYSA-N O=C(C(CCC1)N1S(Cl)(=O)=O)OCc1ccccc1 Chemical compound O=C(C(CCC1)N1S(Cl)(=O)=O)OCc1ccccc1 TXQNSSDPDFIHHW-UHFFFAOYSA-N 0.000 description 1
- MFDVSMAGHZIHJO-UHFFFAOYSA-N O=C(C(F)=C1Nc(ccc(Br)c2)c2F)N(CCC2)C2=C1NS(C1CC1)(=O)=O Chemical compound O=C(C(F)=C1Nc(ccc(Br)c2)c2F)N(CCC2)C2=C1NS(C1CC1)(=O)=O MFDVSMAGHZIHJO-UHFFFAOYSA-N 0.000 description 1
- KPCZPAACELZDAB-UHFFFAOYSA-N O=C(C=C1Nc(ccc(Br)c2)c2F)N(CCC2)C2=C1NS(c1ccc(C(F)(F)F)cc1)(=O)=O Chemical compound O=C(C=C1Nc(ccc(Br)c2)c2F)N(CCC2)C2=C1NS(c1ccc(C(F)(F)F)cc1)(=O)=O KPCZPAACELZDAB-UHFFFAOYSA-N 0.000 description 1
- QKWOYUAMUFVFEP-UHFFFAOYSA-N O=C(NC(C1=C2F)=C(CCC3)N3C2=O)N1c(ccc(Br)c1)c1F Chemical compound O=C(NC(C1=C2F)=C(CCC3)N3C2=O)N1c(ccc(Br)c1)c1F QKWOYUAMUFVFEP-UHFFFAOYSA-N 0.000 description 1
- IFZNGDPNXXZCES-UHFFFAOYSA-N OC(C(C(Nc(ccc(Br)c1)c1F)=C1F)=C(CCC2)N2C1=O)=O Chemical compound OC(C(C(Nc(ccc(Br)c1)c1F)=C1F)=C(CCC2)N2C1=O)=O IFZNGDPNXXZCES-UHFFFAOYSA-N 0.000 description 1
- IPROFDRPBZNCIY-UHFFFAOYSA-N OCC(CONC(C(C(Nc(c(F)c1)ccc1I)=C1Cl)=C(CCC2)N2C1=O)=O)O Chemical compound OCC(CONC(C(C(Nc(c(F)c1)ccc1I)=C1Cl)=C(CCC2)N2C1=O)=O)O IPROFDRPBZNCIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2009/054717 WO2010121646A1 (en) | 2009-04-21 | 2009-04-21 | Heterocyclic compounds as mek inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102458580A true CN102458580A (zh) | 2012-05-16 |
Family
ID=43010696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801598607A Pending CN102458580A (zh) | 2009-04-21 | 2009-04-21 | 作为mek抑制剂的杂环化合物 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2421612A1 (pt) |
| JP (1) | JP2012524114A (pt) |
| KR (1) | KR20120028882A (pt) |
| CN (1) | CN102458580A (pt) |
| AU (1) | AU2009344690A1 (pt) |
| BR (1) | BRPI0925050A2 (pt) |
| CA (1) | CA2761108A1 (pt) |
| EA (1) | EA201101533A1 (pt) |
| MX (1) | MX2011011083A (pt) |
| WO (1) | WO2010121646A1 (pt) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105384754A (zh) * | 2014-09-02 | 2016-03-09 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| CN108640916A (zh) * | 2018-06-07 | 2018-10-12 | 广东药科大学 | 一类具有抗癌活性的硫代吲嗪类化合物及其衍生物 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8022057B2 (en) | 2007-11-12 | 2011-09-20 | Takeda Pharmaceutical Company Limited | MAPK/ERK kinase inhibitors |
| EP2496575B1 (en) * | 2009-11-04 | 2014-04-30 | Novartis AG | Heterocyclic sulfonamide derivatives useful as mek inhibitors |
| MX2013014398A (es) * | 2011-06-09 | 2014-03-21 | Novartis Ag | Derivados de sulfonamida heterociclicos. |
| GB201201332D0 (en) | 2012-01-26 | 2012-03-14 | Imp Innovations Ltd | Method |
| CN104203947A (zh) | 2012-03-14 | 2014-12-10 | 鲁宾有限公司 | 杂环基化合物 |
| LT3702351T (lt) | 2012-10-19 | 2024-01-10 | Array Biopharma, Inc. | Kompozicijos, apimančios mek inhibitorių |
| WO2016009306A1 (en) | 2014-07-15 | 2016-01-21 | Lupin Limited | Heterocyclyl compounds as mek inhibitors |
| WO2016035008A1 (en) | 2014-09-04 | 2016-03-10 | Lupin Limited | Pyridopyrimidine derivatives as mek inhibitors |
| CN109761977B (zh) * | 2019-03-05 | 2020-07-17 | 江西省药品检验检测研究院 | 一种黄精生物碱c及其制备方法与应用 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050049276A1 (en) * | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| US8022057B2 (en) * | 2007-11-12 | 2011-09-20 | Takeda Pharmaceutical Company Limited | MAPK/ERK kinase inhibitors |
-
2009
- 2009-04-21 EP EP09779322A patent/EP2421612A1/en not_active Withdrawn
- 2009-04-21 CA CA2761108A patent/CA2761108A1/en not_active Abandoned
- 2009-04-21 CN CN2009801598607A patent/CN102458580A/zh active Pending
- 2009-04-21 AU AU2009344690A patent/AU2009344690A1/en not_active Abandoned
- 2009-04-21 WO PCT/EP2009/054717 patent/WO2010121646A1/en active Application Filing
- 2009-04-21 EA EA201101533A patent/EA201101533A1/ru unknown
- 2009-04-21 MX MX2011011083A patent/MX2011011083A/es not_active Application Discontinuation
- 2009-04-21 KR KR1020117027486A patent/KR20120028882A/ko not_active Application Discontinuation
- 2009-04-21 BR BRPI0925050-6A patent/BRPI0925050A2/pt not_active IP Right Cessation
- 2009-04-21 JP JP2012506346A patent/JP2012524114A/ja active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105384754A (zh) * | 2014-09-02 | 2016-03-09 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| CN105384754B (zh) * | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| CN108640916A (zh) * | 2018-06-07 | 2018-10-12 | 广东药科大学 | 一类具有抗癌活性的硫代吲嗪类化合物及其衍生物 |
| WO2019232665A1 (zh) * | 2018-06-07 | 2019-12-12 | 广东药科大学 | 一类具有抗癌活性的硫代吲嗪类化合物及其衍生物 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2421612A1 (en) | 2012-02-29 |
| MX2011011083A (es) | 2011-11-04 |
| KR20120028882A (ko) | 2012-03-23 |
| AU2009344690A1 (en) | 2011-10-27 |
| CA2761108A1 (en) | 2010-10-28 |
| JP2012524114A (ja) | 2012-10-11 |
| BRPI0925050A2 (pt) | 2015-08-04 |
| EA201101533A1 (ru) | 2012-05-30 |
| WO2010121646A1 (en) | 2010-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102458580A (zh) | 作为mek抑制剂的杂环化合物 | |
| CN102596951B (zh) | 用作mek抑制剂的杂环磺酰胺衍生物 | |
| KR20060072142A (ko) | Ｃｒｆ 길항제 및 이환식 복소환 화합물 | |
| CA2921300C (en) | 1h-imidazo[4,5-c]quinolinyl compounds, compositions thereof, and their use as mek inhibitors | |
| EP2004653B1 (en) | 3-substituted n-(aryl- or heteroaryl)-pyrazo[1,5-a]pyrimidines as kinase inhibitors | |
| CN104203952A (zh) | 咪唑并吡咯烷酮化合物 | |
| TW200813064A (en) | Purinone derivatives as HM74A agonists | |
| KR20030070593A (ko) | 삼환식 복소환 유도체 화합물 및 그 화합물을 유효성분으로 하는 의약 | |
| NZ588069A (en) | Hydroxamate-based inhibitors of deacetylases b | |
| US20090275606A1 (en) | Heterocyclic Compounds as MEK Inhibitors | |
| JP5456908B2 (ja) | ヘテロ環式スルホンアミド誘導体 | |
| JP2014517004A (ja) | 複素環スルホンアミド誘導体 | |
| AU2007233926A1 (en) | 3-unsubstituted N-(aryl- or heteroaryl)-pyrazolori [1,5-a]pyrimidines as kinase inhibitors | |
| WO2012107500A1 (en) | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase | |
| WO2007017237A1 (en) | Imidazopyridine derivatives as cannabinoid receptor ligands | |
| CN102574853B (zh) | 杂环肟化合物 | |
| Subramanya | 2, Patent Application Publication to, Pub. No.: US 2009/0275606 A1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120516 |